GPP Plays Critical Role in Moving HIV Prevention Research
Agenda Forward
VIENNA, July 23 /PRNewswire-USNewswire/ — The
draft second edition of The Good Participatory Practice (GPP)
Guidelines for Biomedical HIV Prevention Trials were released
yesterday at the International AIDS Conference in Vienna by AVAC. The GPP
Guidelines aim to provide trial funders, sponsors, and
implementers with systematic guidance on how to effectively work
with a range of stakeholders as they design and conduct biomedical
HIV prevention trials.
The guidelines were developed by AVAC and UNAIDS in consultation
with a broad range of global stakeholders who have provided
perspectives since the first edition was published in 2007. AVAC
and UNAIDS are now seeking feedback on the draft second edition
from those with interest and expertise in HIV prevention research
until 31 October, after which the final second edition will be
published.
Clinical trials are guided by Good Clinical Practice, Good
Laboratory Practice, and other guidelines and regulations that
cover scientific and general ethical conduct, but global guidelines
had not existed for community engagement before the first
publication of GPP.
“Recent breakthroughs, including positive results from the
CAPRISA 004 microbicide trial, have reenergized prevention
research, and around the world, thousands of research participants
and hundreds of researchers and trial site staff are working
together find new HIV prevention options. Thousands more will be
needed as we work to find new solutions to ending the AIDS
epidemic,” said Mitchell Warren,
executive director of AVAC.
“The GPP Guidelines were developed to fill an import
‘/>”/>
